The Vetr crowd upgraded their rating for Illumina, Inc. (NASDAQ:ILMN) on Wednesday, from 2 stars (Sell), issued five days ago, to 4 stars (Buy). Crowd sentiment for Illumina is edging cautious, with 62 percent of Vetr user ratings bearish.
The gene sequencing solutions company provided plenty of indications that it's primed for growth in 2017. In the second week of the year, Illumina provided a strong early report on its 2016 Q4 earnings while also launching an improved model of its sequencing platform.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
As a result, the company received a Buy upgrade from Bank of America and shares rose by $23.50, over 16 percent, to $165.04. The price has remained near the the $160 mark since then and ended today at $161.07.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $175.77, which is well above the average analyst target price of the $149.89. Less than 2 percent of Vetr users are holding ILMN in their watch lists.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.